Chinook Therapeutics, Inc. (NASDAQ:KDNY) CEO Purchases $65,150.00 in Stock

Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) CEO Eric Dobmeier purchased 5,000 shares of the stock in a transaction on Wednesday, May 25th. The shares were purchased at an average cost of $13.03 per share, for a total transaction of $65,150.00. Following the acquisition, the chief executive officer now directly owns 205,880 shares of the […]

Related Keywords

Eric Dobmeier ,Securities Exchange Commission ,Zacks Investment Research ,Blackrock Inc ,Samsara Biocapital ,Nasdaq ,Frazier Management ,Frazier Life Sciences Management ,Chinook Therapeutics Inc ,Chinook Therapeutics ,Get Rating ,Exchange Commission ,Track Capital ,Nasdaq Kdny ,Akdny ,Medical ,Insider Trading ,Nsider Trades ,Stocks ,